Jilin Jian Yisheng Pharmaceutical Co Ltd
SZSE:002566
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Jilin Jian Yisheng Pharmaceutical Co Ltd
SZSE:002566
|
CN |
Balance Sheet
Balance Sheet Decomposition
Jilin Jian Yisheng Pharmaceutical Co Ltd
Jilin Jian Yisheng Pharmaceutical Co Ltd
Balance Sheet
Jilin Jian Yisheng Pharmaceutical Co Ltd
| Dec-2008 | Dec-2009 | Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||
| Cash & Cash Equivalents |
23
|
47
|
46
|
884
|
851
|
398
|
312
|
162
|
80
|
81
|
39
|
63
|
287
|
220
|
343
|
488
|
71
|
|
| Cash |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
220
|
343
|
488
|
71
|
|
| Cash Equivalents |
23
|
47
|
46
|
884
|
850
|
398
|
312
|
162
|
80
|
80
|
39
|
63
|
287
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
297
|
82
|
33
|
0
|
4
|
0
|
0
|
0
|
100
|
60
|
103
|
460
|
|
| Total Receivables |
135
|
132
|
161
|
327
|
314
|
350
|
413
|
425
|
437
|
348
|
288
|
275
|
311
|
296
|
287
|
211
|
215
|
|
| Accounts Receivables |
68
|
75
|
88
|
171
|
180
|
163
|
170
|
173
|
202
|
187
|
184
|
186
|
205
|
196
|
190
|
154
|
150
|
|
| Other Receivables |
67
|
57
|
73
|
156
|
135
|
187
|
243
|
253
|
236
|
160
|
105
|
89
|
106
|
100
|
97
|
57
|
65
|
|
| Inventory |
71
|
69
|
99
|
134
|
195
|
476
|
1 212
|
1 449
|
1 622
|
1 666
|
1 679
|
1 634
|
1 616
|
1 597
|
1 603
|
1 617
|
1 626
|
|
| Other Current Assets |
9
|
6
|
7
|
5
|
6
|
19
|
76
|
86
|
18
|
19
|
8
|
11
|
9
|
9
|
9
|
13
|
3
|
|
| Total Current Assets |
238
|
254
|
313
|
1 349
|
1 366
|
1 539
|
2 095
|
2 155
|
2 156
|
2 117
|
2 015
|
1 983
|
2 223
|
2 222
|
2 303
|
2 431
|
2 376
|
|
| PP&E Net |
100
|
160
|
185
|
208
|
230
|
323
|
367
|
403
|
441
|
461
|
466
|
438
|
426
|
503
|
528
|
485
|
451
|
|
| PP&E Gross |
100
|
160
|
185
|
208
|
230
|
323
|
367
|
403
|
441
|
461
|
466
|
438
|
426
|
503
|
528
|
485
|
451
|
|
| Accumulated Depreciation |
40
|
51
|
66
|
85
|
102
|
116
|
130
|
152
|
179
|
213
|
247
|
285
|
322
|
361
|
401
|
442
|
478
|
|
| Intangible Assets |
7
|
9
|
12
|
15
|
17
|
17
|
16
|
60
|
59
|
57
|
55
|
55
|
123
|
120
|
117
|
114
|
111
|
|
| Goodwill |
0
|
0
|
0
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
15
|
|
| Other Long-Term Assets |
2
|
5
|
5
|
5
|
47
|
10
|
11
|
14
|
13
|
16
|
16
|
19
|
22
|
18
|
17
|
15
|
15
|
|
| Other Assets |
0
|
0
|
0
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
|
| Total Assets |
347
N/A
|
428
+23%
|
515
+20%
|
1 579
+206%
|
1 662
+5%
|
1 891
+14%
|
2 490
+32%
|
2 634
+6%
|
2 671
+1%
|
2 654
-1%
|
2 553
-4%
|
2 497
-2%
|
2 796
+12%
|
2 864
+2%
|
2 967
+4%
|
3 047
+3%
|
2 971
-2%
|
|
| Liabilities | ||||||||||||||||||
| Accounts Payable |
7
|
10
|
7
|
12
|
18
|
20
|
135
|
24
|
20
|
26
|
21
|
26
|
25
|
20
|
24
|
25
|
13
|
|
| Accrued Liabilities |
2
|
1
|
4
|
8
|
8
|
15
|
16
|
26
|
22
|
26
|
19
|
20
|
26
|
35
|
31
|
24
|
16
|
|
| Short-Term Debt |
68
|
20
|
40
|
0
|
0
|
100
|
480
|
760
|
719
|
553
|
438
|
291
|
416
|
397
|
430
|
470
|
297
|
|
| Current Portion of Long-Term Debt |
3
|
4
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
10
|
6
|
3
|
2
|
3
|
|
| Other Current Liabilities |
37
|
96
|
87
|
26
|
28
|
46
|
72
|
47
|
76
|
114
|
64
|
59
|
98
|
76
|
99
|
68
|
37
|
|
| Total Current Liabilities |
116
|
131
|
139
|
47
|
56
|
181
|
703
|
857
|
838
|
718
|
542
|
396
|
575
|
534
|
588
|
590
|
366
|
|
| Long-Term Debt |
9
|
4
|
4
|
4
|
3
|
2
|
2
|
2
|
1
|
1
|
11
|
13
|
3
|
11
|
10
|
4
|
156
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
3
|
|
| Minority Interest |
1
|
1
|
1
|
20
|
21
|
21
|
21
|
20
|
60
|
94
|
110
|
126
|
137
|
116
|
94
|
99
|
98
|
|
| Other Liabilities |
3
|
11
|
13
|
14
|
15
|
30
|
34
|
30
|
31
|
37
|
35
|
30
|
87
|
121
|
118
|
119
|
113
|
|
| Total Liabilities |
128
N/A
|
147
+15%
|
156
+6%
|
84
-46%
|
93
+11%
|
235
+151%
|
760
+224%
|
909
+20%
|
930
+2%
|
851
-9%
|
698
-18%
|
564
-19%
|
800
+42%
|
783
-2%
|
812
+4%
|
814
+0%
|
735
-10%
|
|
| Equity | ||||||||||||||||||
| Common Stock |
61
|
61
|
83
|
110
|
221
|
221
|
331
|
331
|
331
|
331
|
331
|
331
|
331
|
331
|
331
|
331
|
331
|
|
| Retained Earnings |
119
|
180
|
237
|
334
|
408
|
496
|
570
|
564
|
577
|
637
|
690
|
767
|
830
|
916
|
989
|
1 068
|
1 070
|
|
| Additional Paid In Capital |
39
|
39
|
39
|
1 050
|
940
|
940
|
830
|
830
|
833
|
835
|
835
|
835
|
835
|
835
|
835
|
835
|
835
|
|
| Total Equity |
219
N/A
|
280
+28%
|
359
+28%
|
1 494
+317%
|
1 569
+5%
|
1 656
+6%
|
1 731
+4%
|
1 725
0%
|
1 741
+1%
|
1 803
+4%
|
1 856
+3%
|
1 932
+4%
|
1 996
+3%
|
2 082
+4%
|
2 155
+4%
|
2 233
+4%
|
2 236
+0%
|
|
| Total Liabilities & Equity |
347
N/A
|
428
+23%
|
515
+20%
|
1 579
+206%
|
1 662
+5%
|
1 891
+14%
|
2 490
+32%
|
2 634
+6%
|
2 671
+1%
|
2 654
-1%
|
2 553
-4%
|
2 497
-2%
|
2 796
+12%
|
2 864
+2%
|
2 967
+4%
|
3 047
+3%
|
2 971
-2%
|
|
| Shares Outstanding | ||||||||||||||||||
| Common Shares Outstanding |
184
|
184
|
248
|
331
|
331
|
331
|
331
|
331
|
331
|
331
|
331
|
331
|
331
|
331
|
331
|
331
|
331
|
|